Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. From Wikipedia
The detailed eight-week induction results, including outcomes in patients who failed prior advanced therapies, will guide expectations for planned 2026 regulatory submissions.
